Cancer clinical trials in the region Nouvelle-Aquitaine
195 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 3
Lung cancer
#NCT05687266
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Locally Advanced
Metastatic
Systemic Treatment-Naive
EGFR
BRAF
MET
ALK
RET
ROS-1
NTRK-1/2/3
Hôpital Cochin (Paris ), Hôpital Bichat - Claude Bernard - AP-HP (Paris), Hôpital Henri-Mondor AP-HP (Créteil), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier), Centre Hospitalier Universitaire de Nîmes (Nîmes) (and 8 more...)
AstraZeneca
Phase 3
Lung cancer
#NCT05668988
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
EGFR
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Nantes (Nantes), Hôpital d'instruction des Armées Bégin (Saint-Mandé), Centre Hospitalier Universitaire Angers (Angers ), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Centre Hospitalier Universitaire de Grenoble (La Tronche) (and 7 more...)
Debiopharm International SA
Phase 3
Breast cancer
#NCT05296798
HER2 Positive
HR Positive
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Institut Sainte Catherine (Avignon), Centre Hospitalier de la Côte Basque (Bayonne), Centre Hospitalier Universitaire de Besançon (Besançon), Polyclinique Bordeaux Nord Aquitaine (Bordeaux), Centre Hospitalier Universitaire de Grenoble (La Tronche) (and 4 more...)
Hoffmann-La Roche
Phase 3
Lung cancer
#NCT05555732
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
EGFR
BRAF
MET
ALK
RET
ROS-1
NTRK-1/2/3
Other mutation
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Immunotherapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Léon Bérard (Lyon), Hôpital Foch (Suresnes) (and 5 more...)
Daiichi Sankyo
Phase 3
Breast cancer
#NCT05514054
HER2 Negative
HR Positive
Localized
Hormone therapy
Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Besançon (Besançon), Polyclinique de Blois (La Chaussée-Saint-Victor), Groupe Hospitalier La Rochelle-Ré-Aunis (La Rochelle), Clinique Chénieux (Limoges) (and 31 more...)
Eli Lilly et compagnie
Phase 3
Lymphoma
#NCT05508867
Hodgkin lymphoma
None
Immunotherapy
1
2
3 or more
Systemic Treatment-Naive
Allogeneic stem cell transplant
Centre Hospitalier Universitaire Dupuytren (Limoges), Hôpital Henri-Mondor AP-HP (Créteil), IUCT Oncopôle (Toulouse), Centre Léon Bérard (Lyon), CHU de Rennes - Hôpital Pontchaillou (Rennes)
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT04790253
SCLC (Small Cell Lung Cancer)
Chemotherapy
Chemotherapy
Centre Henri Becquerel (Rouen ), Institut Bergonié (Bordeaux), Gustave Roussy (Villejuif), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Hôpital Lyon Sud - Hospices Civils de Lyon (Pierre-Bénite) (and 7 more...)
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Breast cancer
#NCT05382286
HER2 Negative
HR Negative
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Immunotherapy
Immunotherapy
Bispecific T-cell engager antibodies
Institut Sainte Catherine (Avignon), Centre Hospitalier Universitaire de Besançon (Besançon), Polyclinique Bordeaux Nord Aquitaine (Bordeaux), Centre François Baclesse (Caen ), Centre Jean Perrin (Clermont Ferrand ) (and 9 more...)
Gilead Sciences
Phase 3
Lymphoma
#NCT05371093
B cell lymphoma
Follicular lymphoma
None
Chemotherapy
Targeted therapy
1
2
3 or more
Systemic Treatment-Naive
Car-T
Centre Henri Becquerel (Rouen ), Centre Hospitalier Universitaire de Montpellier - Site de Saint Eloi (Montpellier), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Henri-Mondor AP-HP (Créteil), Institut Paoli-Calmettes (Marseille) (and 6 more...)
Kite, A Gilead Company
Phase 3
Lung cancer
#NCT05215340
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Systemic Treatment-Naive
PDL1 Positive (>= 50%)
EGFR
BRAF
MET
ALK
RET
ROS-1
NTRK-1/2/3
Immunotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Immunotherapy
Chemotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
Institut Bergonié (Bordeaux), Centre Hospitalier Universitaire de Lille (Lille), Centre Hospitalier Universitaire de Montpellier - Site Arnaud de Villeneuve (Montpellier), Hôpital Tenon AP-HP (Paris ), Hôpital Foch (Suresnes) (and 6 more...)
Daiichi Sankyo